Genentech Alzheimer's drug misses goals in studies - KXXV-TV News Channel 25 - Central Texas News and Weather for Waco, Temple, Killeen |

Genentech Alzheimer's drug misses goals in studies

Posted: Updated:
  • NationalMore>>

  • Mother, daughter die after Philly food truck blast

    Mother, daughter die after Philly food truck blast

    Thursday, July 24 2014 12:53 PM EDT2014-07-24 16:53:53 GMT
    A mother and teenage daughter have died of injuries they suffered in a fiery explosion inside their food truck earlier this month, authorities said Thursday.More >>
    A mother and teenage daughter have died of injuries they suffered in a fiery explosion inside their food truck earlier this month, authorities said Thursday.More >>
  • Varying health premium subsidies worry consumers

    Varying health premium subsidies worry consumers

    Thursday, July 24 2014 12:44 PM EDT2014-07-24 16:44:49 GMT
    Linda Close was grateful to learn she qualified for a sizable subsidy to help pay for her health insurance under the new federal law. But in the process of signing up for a plan, Close said her HealthCare.gov...More >>
    Linda Close was grateful to learn she qualified for a sizable subsidy to help pay for her health insurance under the new federal law. But in the process of signing up for a plan, Close said her HealthCare.gov account...More >>
  • Gov: Senator in plagiarism row deserves respect

    Gov: Senator in plagiarism row deserves respect

    Thursday, July 24 2014 12:38 PM EDT2014-07-24 16:38:53 GMT
    Sen. John Walsh said his unattributed use of others' work in his master's thesis was not plagiarism but "a few citations that were unintentionally left out of a term paper" that he blamed in part on...More >>
    Montana Gov. Steve Bullock says he didn't know that Sen. John Walsh had plagiarized parts of his master's thesis when he appointed the former National Guard general to the Senate earlier this year.More >>
By MARILYNN MARCHIONE
AP Chief Medical Writer

An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.

Pneumonia and deaths were more common among those receiving the drug, but researchers downplayed that. Study leader Dr. Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people.

"We're very encouraged" by the hint of benefit for patients with milder dementia and will talk with regulators about next steps for the drug, crenezumab (cruh-NEZ-oo-mab), said a Genentech scientist, Dr. Carole Ho. The results fit with other evidence suggesting that treating earlier in the course of the disease is better, she said.

Results were revealed Wednesday at the Alzheimer's Association International Conference in Copenhagen.

They are the latest mixed bag on treatments aimed at clearing away the sticky amyloid plaques clogging Alzheimer's patients' brains. About 35 million people worldwide have Alzheimer's, the most common form of dementia. There is no cure and current treatments only temporarily ease symptoms.

Last year, an Eli Lilly & Co. medicine, solanezumab, that also sought to clear away amyloid missed main goals in two studies but combined results suggested it might help people with milder disease. It's in further study now. Before that, bapineuzumab, a similar drug being developed by Pfizer Inc. and Johnson & Johnson, showed promise in mid-stage testing but flopped in larger, more definitive trials.

The Genentech drug has been closely watched because it targets amyloid more broadly than the other drugs do, and the California-based company has a long track record of success with many biological medicines against cancer.

Mid-stage studies aim to give some idea of safety and whether the drug is effective enough to advance to larger, more definitive studies aimed at winning market approval.

In one study, 431 patients ages 50 to 80 with mild to moderate Alzheimer's were given crenezumab or dummy drug as shots every two weeks, or as a higher dose in infusions every four weeks for 17 months. No significant difference was seen among the groups on two widely used measures of thinking and functioning skills.

However, the 70 most mildly impaired participants who received the higher dose declined 35 percent less on the cognitive measure than the 33 mildly impaired people given dummy infusions. The difference was about 3.5 points on the roughly 70-point scale - "equivalent to six or nine months" of delay in decline, Cummings said.

This result isn't definitive, though, and can only be considered a signal worth exploring in future research because it didn't involve the whole group tested. And even in this mildly impaired group, the drug did not improve the second measure, ability to function in daily life.

In the second study, 73 people who showed amyloid plaques on brain imaging also were given crenezumab or dummy shots or infusions. The main outcome - levels of amyloid seen on brain imaging after treatment - will be presented at a medical conference in November. Results on cognitive function seem to mirror those in the larger study, Cummings said.

Five people given crenezumab died - one from sudden death, two from respiratory failure, one from pneumonia and one from worsening Alzheimer's.

"We believe that the safety profile is acceptable," because deaths do not seem related to the drug, Genentech's Ho said. "It is not a show stopper."

Genentech and its corporate parent, Switzerland-based Roche Holding AG, paid for the study and Cummings is a paid adviser to Genentech.

In a statement Wednesday, the Alzheimer's Association noted that crenezumab was being tested in another study aimed at preventing the disease, and said the new results give hope it will be more successful in that setting.

___

Online:

National Institute on Aging: http://www.nia.nih.gov/Alzheimers

Patient, family info: http://www.alzheimers.gov/

Alzheimer's Association: http://www.alz.org

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

  • U.S. & World NewsMore>>

  • US pulls Peace Corps volunteers from Kenya

    US pulls Peace Corps volunteers from Kenya

    Thursday, July 24 2014 12:55 PM EDT2014-07-24 16:55:03 GMT
    The Peace Corps says it is suspending its operations in Kenya and pulling out more than 50 volunteers because of security concerns.More >>
    The Peace Corps is suspending its programs in Kenya because of security concerns and is pulling more than 50 volunteers out of the country until threat levels decrease, the Peace Corps and State Department said Thursday.More >>
  • House advances lawsuit bill

    House advances lawsuit bill

    Thursday, July 24 2014 12:53 PM EDT2014-07-24 16:53:46 GMT
    Republicans have cleared legislation for a vote in the House that authorizes the filing of an election-year lawsuit accusing President Barack Obama of failing to implement the 4-year-old health care law.More >>
    Republicans have cleared legislation for a vote in the House that authorizes the filing of an election-year lawsuit accusing President Barack Obama of failing to implement the 4-year-old health care law.More >>
  • Agents get subsidized 'Obamacare' using fake IDs

    Agents get subsidized 'Obamacare' using fake IDs

    Thursday, July 24 2014 12:44 PM EDT2014-07-24 16:44:17 GMT
    Congress will hear testimony Wednesday detailing how undercover investigators used fake identities to get taxpayer-subsidized health insurance under President Barack Obama's law.More >>
    Undercover investigators using fake identities were able to secure taxpayer-subsidized health insurance under President Barack Obama's health care law, congressional investigators said Wednesday.More >>
Powered by WorldNow

News Channel 25 KXXV-TV
P.O. Box 2522
Waco, TX 76702

Phone Numbers:
Main: 254-754-2525
Tip Line: 254-757-2525

Links
Contact Us
KXXV Employment Opportunites
FCC Filings
Advertise on KXXV

Can't find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KXXV. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.